Our findings confirm that GFAP can capture key elements of disease burden, including neurodevelopmental delay, epilepsy, and comorbidities, while being sensitive to genetic variations such as deletion size and the presence of additional chromosomal rearrangements. Here, GFAP is linked to epilepsy.